Somerset, N.J. – March 10, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Dr. Gregory Bleck, Global Head of R&D, Catalent Biologics, will be presenting at the upcoming BioProcess International West Conference, to be held at the Oakland Marriott City Center Hotel, Oakland, CA, on March 14th – 17th, 2016.
Dr. Bleck’s presentation, on Tuesday, March 15th, at 11.50 a.m., is entitled “Optimization of a Specific Enzyme Conversion Step to Generate High-Titer, Fully Processed Antibody in CHO Cells,” and will discuss the challenges of expressing more complex biomolecules that require multiple proteins to be produced in order to generate a functional molecule. As the number of more complex biopharmaceuticals in development continues to increase, processes and technologies need to be developed and optimized that support these types of programs. Dr. Bleck will outline a case study where these challenges were overcome and discuss the successful cell line and process development for an antibody protein, where the antibody required additional processing by a site-specific enzyme for correct functionality.
Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics, before becoming Global Head of R&D, Biologics, in 2013. Dr. Bleck holds a Bachelor’s degree in Dairy Science and a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Dr. Bleck has published more than 55 research papers and co-authored chapters in three books.
For more information on the BioProcess International West exhibition and conference, visit: http://www.ibclifesciences.com/BPIWest/overview.xml and to arrange a meeting with a Dr. Bleck, contact Richard Kerns at NEPR- firstname.lastname@example.org.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™